These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

973 related articles for article (PubMed ID: 30105577)

  • 41. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ion Torrent ™ Genexus ™ Integrated Sequencer and ForeNGS Analysis Software-An automatic NGS-STR workflow from DNA to profile for forensic science.
    Guo F; Lang Y; Long G; Liu Z; Jing G; Zhou Y; Zhang B; Yu S
    Forensic Sci Int Genet; 2022 Nov; 61():102753. PubMed ID: 35931007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-generation sequencing in the clinic: promises and challenges.
    Xuan J; Yu Y; Qing T; Guo L; Shi L
    Cancer Lett; 2013 Nov; 340(2):284-95. PubMed ID: 23174106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples.
    Mehrotra M; Luthra R; Abraham R; Mishra BM; Virani S; Chen H; Routbort MJ; Patel KP; Medeiros LJ; Singh RR
    Cancer Genet; 2017 Apr; 212-213():24-31. PubMed ID: 28449808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
    Choudhary A; Mambo E; Sanford T; Boedigheimer M; Twomey B; Califano J; Hadd A; Oliner KS; Beaudenon S; Latham GJ; Adai AT
    BMC Med Genomics; 2014 Nov; 7():62. PubMed ID: 25395014
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
    Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
    PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
    Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
    J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted exome sequencing and chromosomal microarray for the molecular diagnosis of nevoid basal cell carcinoma syndrome.
    Matsudate Y; Naruto T; Hayashi Y; Minami M; Tohyama M; Yokota K; Yamada D; Imoto I; Kubo Y
    J Dermatol Sci; 2017 Jun; 86(3):206-211. PubMed ID: 28342698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
    Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
    PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
    Tsongalis GJ; Peterson JD; de Abreu FB; Tunkey CD; Gallagher TL; Strausbaugh LD; Wells WA; Amos CI
    Clin Chem Lab Med; 2014 May; 52(5):707-14. PubMed ID: 24334431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
    Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
    Mol Diagn Ther; 2020 Jun; 24(3):339-349. PubMed ID: 32306292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrative molecular profiling of routine clinical prostate cancer specimens.
    Grasso CS; Cani AK; Hovelson DH; Quist MJ; Douville NJ; Yadati V; Amin AM; Nelson PS; Betz BL; Liu CJ; Knudsen KE; Cooney KA; Feng FY; McDaniel AS; Tomlins SA
    Ann Oncol; 2015 Jun; 26(6):1110-1118. PubMed ID: 25735316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
    Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
    Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
    Normanno N; Machado JC; Pescarmona E; Buglioni S; Navarro L; Esposito Abate R; Ferro A; Mensink R; Lambiase M; Lespinet-Fabre V; Calgua B; Jermann PM; Ilié M; Hofman P
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology.
    Barua S; Hsiao S; Clancy E; Freeman C; Mansukhani M; Fernandes H
    J Clin Pathol; 2023 Dec; 77(1):46-53. PubMed ID: 36376073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing.
    Dacheva D; Dodova R; Popov I; Goranova T; Mitkova A; Mitev V; Kaneva R
    Mol Diagn Ther; 2015 Apr; 19(2):119-30. PubMed ID: 25893891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
    George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
    Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indel sensitive and comprehensive variant/mutation detection from RNA sequencing data for precision medicine.
    Prodduturi N; Bhagwate A; Kocher JA; Sun Z
    BMC Med Genomics; 2018 Sep; 11(Suppl 3):67. PubMed ID: 30255803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.